Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.47

+0.3%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1092)	5/16/2000 2:27:00 PM
From: Biomaven	Read Replies (1) of 52153

Cowen weighs in on some of my favorite stocks: Headline: RESEARCH ALERT - SG Cowen starts biotechs at str buy ================================================================ NEW YORK, May 16 (Reuters) - SG Cowen said Tuesday it was initiating coverage on three companies in the biotechnology sector. Biotechnology company Genzyme Molecular Oncology (NASDAQ:GZMO) was started with a strong buy rating and a $25 price target. Shares of Genzyme Molecular were up 2-7/8 at 17-7/8. -- said it assembled broad technology platform to develop cancer therapeutics. -- said multiple modalities should improve likelihood of success. -- said anticipate significant efficacy visibility of therapeutics over next year. First product could reach market in 2004. -- said academic collaborations provide access to leading-edge technologies and theory. -- said comparative analysis suggests stock is substantially undervalued. Gene therapy researcher Genzyme Transgenics Corp. (NASDAQ:GZTC) was started with a strong buy rating and a $28 price target. Shares of Genzyme Transgenics were up 1-7/8 at 19-7/8. -- said it is a leader in protein therapeutic production using transgenic animals. -- said multiple partnerships validate production platform, and the focus on monoclonal antibodies should maximize capture of value. -- said efficacy of transgenically derived protein demonstrated in ATIII clinical trials. -- said anticipate increased deal flow in outgoing years. Biopharmaceutical company Millennium Pharmaceuticals Inc. (NASDAQ:MLNM) was started with a strong buy rating. -- said first-of-its-kind platform encompasses large-scale genetics, genomics, high-throughput screening, and informatics technologies that have been sourced within and from other companies. Shares of Millennium were up 4-3/16 at 87. -- said focus is gene and target identification. -- said anticipate additional $700 million in partnership revenue this year. Copyright 2000, Reuters News Service This attracted some attention today: cbs.marketwatch.com Maybe the analysts/underwriters are finally peeking their heads out from their bomb-shelters? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next